DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for ovarian carcinoma — screening already-approved drugs against its 46-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOvarian carcinoma maps to a 46-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ovarian carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase (ABO) — ABO is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 6-deoxy-alpha-l-galactopyranosyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4Y63 · 1.3 Å · ligand octyl 2-O-(6-deoxy-alpha-L-galactopyranosyl)-beta-D-galactopyranoside (BHE). Experimental structure, not a prediction.
What the evidence adds up to
A 1992 study compared 25 patients who received three courses of intraperitoneal chemotherapy after second-look laparotomy against 12 patients who received no additional treatment after complete clinical remission. There was a trend toward better survival in the intraperitoneal group, but no difference in the progression-free interval. The authors concluded that more effective consolidation treatment is needed. No response rates or survival times were given.
A 1997 phase I trial tested a single intravenous infusion of the chimeric monoclonal antibody c-MOv18 in 15 ovarian carcinoma patients at doses from 5 mg to 75 mg. Side effects at 50 mg or higher were fever, headache, and nausea or vomiting, all grade II or lower. No human-antichimeric antibody response was detected up to 12 weeks. The absolute amount of antibody in tumour tissue increased with dose. The study was designed only to assess safety and biodistribution, not efficacy; no tumour response data were reported.
The 2012 book chapter is a general review of molecular biology and basic science in ovarian cancer. It does not report any clinical trial results, survival data, or specific drug outcomes.
No randomised controlled trial has yet shown that any repurposed drug improves overall survival in ovarian carcinoma. The available evidence consists of small, non-randomised studies and phase I safety data. What is missing is adequately powered randomised trials, prospective biomarker stratification to identify which patients might benefit, and dedicated funding for such trials.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
InTech eBooks · 2012 · 29 citations
Ovarian Cancer - Basic Science Perspective
AbstractWorldwide, Ovarian carcinoma continues to be responsible for more deaths than all other gynecologic malignancies combined. International leaders in the field address the critical biologic and basic science issues relevant to the disease. The book details the molecular biological aspects of ovarian cancer. It provides molecular biology techniques of understanding this cancer. The techniques are designed to determine tumor genetics, expression, and protein function, and to elucidate the genetic mechanisms by which gene and immunotherapies may be perfected. It provides an analysis of current research into aspects of malignant transformation, growth control, and metastasis. A comprehensive spectrum of topics is covered providing up to date information on scientific discoveries and management considerations.
Intraperitoneal chemotherapy versus no treatment in patients with ovarian carcinoma who are in complete clinical remission
AbstractBACKGROUND: The optimal management of patients with ovarian carcinoma who are in complete clinical remission after completion of postoperative cisplatin-based chemotherapy has not been established. METHODS: In this study, the outcomes of two groups of such patients were compared. One group of 25 patients underwent a second-look laparotomy and subsequently received three courses of intraperitoneal chemotherapy (IP group). The other group of 12 patients was not reexplored and received no additional treatment (NT group). RESULTS: A trend for better survival in the IP group was found compared with the NT group. There was no difference in the duration of the progression-free interval. CONCLUSIONS: More effective treatment for the consolidation of complete clinical remission in patients with ovarian carcinoma is needed.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
